Impact of organ-on-a-chip technology on pharmaceutical R&D costs

Nora Franzen, W. H. van Harten, Valesca P. Retèl, P. Loskill, J. van den Eijnden-van Raaij, Maarten IJzerman*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

95 Citations (Scopus)
273 Downloads (Pure)


Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

Original languageEnglish
Pages (from-to)1720-1724
Number of pages5
JournalDrug discovery today
Issue number9
Early online date8 Jun 2019
Publication statusPublished - 1 Sept 2019


Dive into the research topics of 'Impact of organ-on-a-chip technology on pharmaceutical R&D costs'. Together they form a unique fingerprint.

Cite this